Epidemiology, pathogenesis, and treatment of the common cold

Annals of Allergy, Asthma and Immunology

Volumn 78, Issue 6, 1997, Pages 531-540

  Turner, Ronald B ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA INTERFERON; ALPHA2B INTERFERON; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; ATROPINE; BRADYKININ ANTAGONIST; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLEMASTINE FUMARATE; CODEINE; DECONGESTIVE AGENT; DEXTROMETHORPHAN; EXPECTORANT AGENT; GUAIFENESIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; IPRATROPIUM BROMIDE; MONOCLONAL ANTIBODY; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYMETAZOLINE; PIRODAVIR; STEROID; XYLOMETAZOLINE; ZINC;

CLINICAL FEATURE; COMMON COLD; COUGHING; HUMAN; HUMAN RHINOVIRUS; HYPERTENSION; IMMUNE RESPONSE; INCIDENCE; INFLUENZA VIRUS; INTRANASAL DRUG ADMINISTRATION; NOSE IRRITATION; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHINORRHEA; SORE THROAT; TOPICAL DRUG ADMINISTRATION; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 0030951318     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63213-9     Document Type: Review

References (130)

1. Dingle JH, Badger GF, Jordan WS, Jr. Illness in the home: a study of 25,000 illnesses in a group of Cleveland families. Cleveland: Case Western Reserve University Press, 1964: 33-96.
2. Gwaltney JM, Jr, Hendley JO, Simon G, Jordan WS, Jr. Rhinovirus infections in an industrial population. I. The occurrence of illness. N Engl J Med 1966;275:1261-8.
3. HHS: Vital Health Statistics 10. Washington, D.C., 1986.
4. Rosenthal I. Expense of physician care spurs OTC, self-care market. Drug Topics 1988;132:62-3.
5. Kogan MD, Pappas G, Yu SM, Kotelchuck M. Over-the-counter medication use among US preschool-age children. JAMA 1994;272:1025-30.
6. Monto AS, Cavallaro JJ. The Tecumseh study of respiratory illness. II. Patterns of occurrence of infection with respiratory pathogens, 1965-1969. Am J Epidemiol 1971; 94:280-9.
7. Johnston SL, Pattemore PK, Sanderson G, et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996;154:654-60.
8. Tyrrell DA, Cohen S, Schlarb JE. Signs and symptoms in common colds. Epidemiol Infect 1993;111: 143-56.
9. Harris JM, II, Gwaltney JM, Jr. Incubation periods of experimental rhinovirus infection and illness. J Infect Dis 1996;23:1287-90.
10. Gwaltney JM, Jr, Hendley JO, Simon G, Jordan WS, Jr. Rhinovirus infections in an industrial population. II. Characteristics of illness and antibody response. JAMA 1967;202: 494-500.
11. Turner RB, Witek TJ, Jr, Riker DK. Comparison of symptom severity in natural and experimentally induced colds. Am J Rhinol 1996;10:167-72.
12. Frank AL, Taber LH, Wells CR, et al. Patterns of shedding myxoviruses and paramyxoviruses in children. J Infect Dis 1981;144:433-41.
13. Winther B, Gwaltney JM, Jr, Mygind N, et al. Sites of rhinovirus recovery after point inoculation of the upper airway. JAMA 1986;256:1763-7.
14. Monto AS, Ullman BM. Acute respiratory illness in an American community: the Tecumseh study. JAMA 1974;227:164-9.
15. Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 1993;110: 145-60.
16. Wald ER, Dashefshy B, Byers C, et al. Frequency and severity of infections in day care. J Pediatr 1988;112: 540-6.
17. Hurwitz ES, Gunn WJ, Pinsky PF, Schonberger LB. Risk of respiratory illness associated with day-care attendance: a nationwide study. Pediatr 1991;87:62-9.
18. Fleming DW, Cochi SL, Hightower AW, Broome CV. Childhood upper respiratory tract infections: to what degree is incidence affected by day-care attendance. Pediatr 1987;79:55-60.
19. D'Alessio DJ, Peterson JA, Dick CR, Dick EC. Transmission of experimental rhinovirus colds in volunteer married couples. J Infect Dis 1976; 133:28-36.
20. Meschievitz CK, Schultz SB, Dick EC. A model for obtaining predictable natural transmission of rhinoviruses in human volunteers. J Infect Dis 1984;150:195-201.
21. D'Alessio DJ, Meschievitz CK, Peterson JA, et al. Short-duration exposure and the transmission of rhinoviral colds. J Infect Dis 1984;150: 189-94.
22. Dick EC, Jennings LC, Mink KA, et al. Aerosol transmission of rhinovirus colds. J Infect Dis 1987;156:442-8.
23. Gwaltney JM, Jr, Moskalski PB, Hendley JO. Hand-to-hand transmission of rhinovirus colds. Ann Intern Med 1978;88:463-7.
24. Hendley JO, Gwaltney JM, Jr. Mechanisms of transmission of rhinovirus infections. Epidemiol Rev 1988;10: 243-58.
25. Hall CB, Douglas RG, Jr. Modes of transmission of respiratory syncytial virus. J Pediatr 1981;99:100-3.
26. Douglas RG, Jr. Influenza in man. In: Kilbourne ED, ed. The influenza viruses and influenza. New York: Academic Press, 1975:385-447.
27. Moser MR, Bender TR, Margolis HS, et al. An outbreak of influenza aboard a commercial airliner. Am J Epidemiol 1979;110:1-6.
28. Hendley JO, Edmonson WP, Jr, Gwaltney JM, Jr. Relation between naturally acquired immunity and infectivity of two rhinoviruses in volunteers. J Infect Dis 1972;125:243-8.
29. Hendley JO, Wenzel RP, Gwaltney JM, Jr. Transmission of rhinovirus colds by self-inoculation. N Engl J Med 1973;288:1361-4.
30. Turner RB, Winther B, Hendley JO, et al. Sites of virus recovery and antigen detection in epithelial cells during experimental rhinovirus infection. Acta Otolaryngol (Suppl) 1984;413: 9-14.
31. Arruda E, Boyle TR, Winther B, et al. Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization. J Infect Dis 1995;171:1329-33.
32. Turner RB, Hendley JO, Gwaltney JM, Jr. Shedding of infected ciliated epithelial cells in rhinovirus colds. J Infect Dis 1982;145:849-53.
33. Gwaltney JM, Jr, Phillips CD, Miller RD, Riker DK. Computed tomographic study of the common cold. N Engl J Med 1994;330:25-30.
34. Turner RB. Elaboration of interleukin 8 from fibroblast cells and human nasal epithelium in response to rhinovirus challenge [Abstract B43]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL, Am Soc Microbiol, 1994:65.
35. Halperin SA, Eggleston PA, Hendley JO, et al. Pathogenesis of lower respiratory tract symptoms in experimental rhinovirus infection. Am Rev Respir Dis 1983;128:806-10.
36. Calhoun WJ, Dick EC, Schwartz LB, Busse WW. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest 1994;94:2200-8.
37. Douglas RG, Jr. Pathogenesis of rhinovirus common colds in human volunteers. Ann Otol Rhinol Laryngol 1970;79:563-71.
38. Igarashi Y, Skoner DP, Doyle WJ, et al. Analysis of nasal secretions during experimental rhinovirus upper respiratory infections. J Allergy Clin Immunol 1993;92:722-31.
39. Winther B, Farr B, Turner RB, et al. Histopathologic examination and enumeration of polymorphonuclear leukocytes in the nasal mucosa during experimental rhinovirus colds. Acta Otolaryngol (Stockh) 1984: 19-24.
40. Winther B, Brofeldt S, Christensen B, Mygind N. Light and scanning electron microscopy of nasal biopsy material from patients with naturally acquired common colds. Acta Otolaryngol (Stockh) 1984;97:309-18.
41. Winther B, Gwaltney JM, Jr, Hendley JO. Respiratory virus infection of monolayer cultures of human nasal epithelial cells. Am Rev Respir Dis 1990;141:839-45.
42. Cate TR, Couch RB, Johnson KM. Studies with rhinovirus in volunteers: Production of illness, effect of naturally acquired antibody, and demonstration of a protective effect not associated with serum antibody. J Clin Invest 1964;43:56-67.
43. Cate TR, Rossen RD, Douglas R, Jr, et al. The role of nasal secretion and serum antibody in the rhinovirus common cold. Am J Epidemiol 1966; 84:352-63.
44. Rossen RD, Kasel JA, Couch RB. The secretory immune system: Its relation to respiratory viral infection. Prog Med Virol 1971;13:194-238.
45. Perkins JC, Tucker DN, Knopf HL, et al. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Am J Epidemiol 1969;90:519-26.
46. Barclay WS, Al-Nakib W. An ELISA for the detection of rhinovirus specific antibody in serum and nasal secretions. J Virol Methods 1987;15: 53-64.
47. Douglas RG, Jr, Alford RH, Cate TR, Couch RB. The leukocyte response during viral respiratory illness in man. Ann Intern Med 1966;64: 521-30.
48. Naclerio RM, Proud D, Lichtenstein LM, et al. Kinins are generated during experimental rhinovirus colds. J Infect Dis 1988;157:133-42.
49. Levandowski RA, Ou DW, Jackson GG. Acute-phase decrease of T lymphocyte subsets in rhinovirus infection. J Infect Dis 1986;153:743-8.
50. Skoner DP, Whiteside TL, Wilson JW, et al. Effect of rhinovirus 39 infection on cellular immune parameters in allergic and nonallergic subjects. J Allergy Clin Immunol 1993; 92:732-43.
51. Winther B. Effects on the nasal mucosa of upper respiratory viruses (common cold). Dan Med Bull 1994; 41:193-204.
52. Levandowski RA, Weaver CW, Jackson GG. Nasal-secretion leukocyte populations determined by flow cytometry during acute rhinovirus infection. J Med Virol 1988;25:423-32.
53. Eggleston PA, Hendley JO, Gwaltney JM, Jr, et al. Histamine in nasal secretions. Int Arch Allergy Appl Immunol 1978;57:193-200.
54. Eggleston PA, Hendley JO, Gwaltney JM, Jr. Mediators of immediate hypersensitivity in nasal secretions during natural colds and rhinovirus infection. Acta Otolaryngol Suppl 1984;413:25-35.
55. Proud D, Naclerio RM, Gwaltney JM, Jr, Hendley JO. Kinins are generated in nasal secretions during natural rhinovirus colds. J Infect Dis 1990;161:120-3.
56. Proud D, Reynolds CJ, LaCapra S, et al. Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis 1988; 137:613-6.
57. Higgins PG, Barrow GI, Tyrrell DA. A study of the efficacy of the bradykinin antagonist, NPC 567, in rhinovirus infections in human volunteers. Antiviral Res 1990;14:339-44.
58. Gustafson M, Proud D, Hendley JO, et al. Oral prednisone therapy in experimental rhinovirus infections. J Allergy Clin Immunol 1996;97: 1009-14.
59. Proud D, Gwaltney JM, Jr, Hendley JO, et al. Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds. J Infect Dis 1994; 169:1007-13.
60. Zhu Z, Tang W, Ray A, et al. Rhinovirus stimulation of interleukin-6 in vivo and in vitro: evidence for nuclear factor kB-dependent transcriptional activation. J Clin Invest 1996; 97:421-30.
61. Turner RB, Weingand K, Yeh CH, et al. Association between interleukin-8 (IL-8) and symptom severity in rhinovirus colds [Abstract H48]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Am Soc Microbiol, 1996: 171.
62. Douglas JA, Dhami D, Gurr CE, et al. Influence of interleukin-8 challenge in the nasal mucosa in atopic and nonatopic subjects. Am J Respir Crit Care Med 1994;150:1108-13.
63. Aquilina AT, Hall WJ, Douglas RG, Jr, Utell MJ. Airway reactivity in subjects with viral upper respiratory tract infections: the effects of exercise and cold air. Am Rev Respir Dis 1980;122:3-10.
64. Empey DW, Laitinen LA, Jacobs L, et al. Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory infection. Am Rev Respir Dis 1976;113:131-9.
65. Zerial A, Werner GH, Phillpotts RJ, et al. Studies on 44 081 R.P., a new antirhinovirus compound, in cell cultures and in volunteers. Antimicrob Agents Chemother 1985;27:846-50.
66. Woods MG, Diana GD, Rogge MC, et al. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Anlimicrob Agents Chemother 1989;33: 2069-74.
67. Rozhon E, Cox S, Buontempo P, et al. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Res 1993;21: 15-35.
68. Kenny MT, Dulworth JK, Torney HL. In vitro and in vivo antipicornavirus activity of some phenoxypyridinecarbonitriles. Antimicrob Agents Chemother 1985;28:745-50.
69. Ishitsuka H, Ninomiya YT, Ohsawa C, et al. Direct and specific inactivation of rhinovirus by chalcone Ro 090410. Antimicrob Agents Chemother 1982;22:617-21.
70. DeLong DC, Reed SE. Inhibition of rhinovirus replication in organ culture by a potential antiviral drug. J Infect Dis 1980;141:87-91.
71. Came PE, Schafer TW, Silver GH. Sensitivity of rhinoviruses to human leukocyte and fibroblast interferons. J Infect Dis 1976;133 Suppl:A136-9.
72. Andries K, Dewindt B, Snoeks J, et al. In vitro activity of Pirodavir (R 77975), a substituted phenoxypyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother 1992;36: 100-7.
73. Abraham G, Colonno RJ. Many rhinovirus serotypes share the same cellular receptor. J Virol 1984;51: 340-5.
74. Colonno RJ, Callahan PL, Long WJ. Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses. J Virol 1986;57:7-12.
75. Greve JM, Davis G, Meyer AM, et al. The major human rhinovirus receptor is ICAM-1. Cell 1989;56:839-47.
76. Staunton DE, Merluzzi VJ, Rothlein R, et al. A cell adhesion molecule, ICAM-1 is the major surface receptor for rhinoviruses. Cell 1989;56: 849-53.
77. Marlin SD, Staunton DE, Springer TA, et al. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature 1990; 344:70-2.
78. Crump CE, Arruda E, Hayden FG. In vitro inhibitory activity of soluble ICAM-1 for the numbered serotypes of human rhinovirus. Antiviral Chem Chemother 1993;4:323-7.
79. Condra JH, Sardana VV, Tomassini JE, et al. Bacterial expression of antibody fragments that block human rhinovirus infection of cultured cells. J Biol Chem 1990;265:2292-5.
80. de Arruda E, Crump CE, Marlin SD, et al. In vitro studies of the antirhinovirus activity of soluble intercellular adhesion molecule-1. Antimicrob Agents Chemother 1992;36: 1186-91.
81. Korant BD, Kauer JC, Butterworth BE. Zinc ions inhibit replication of rhinoviruses. Nature (London) 1974; 248:588-90.
82. Al-Nakib W, Higgins PG, Barrow I, et al. Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J Antimicrob Chemother 1987;20:893-901.
83. Farr BM, Conner EM, Betts RF, et al. Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrob Agents Chemother 1987;31:1183-7.
84. Smith DS, Helzner EC, Nuttall CE, Jr, et al. Failure of zinc gluconate in treatment of acute upper respiratory tract infections. Antimicrob Agents Chemother 1989;33:646-8.
85. Mossad SB, Macknin ML, Medendorp SV, Mason P. Zinc gluconate lozenges for treating the common cold: a randomized, double-blind, placebo-controlled study. Ann Intern Med 1996;125:81-8.
86. Eby GA, Davis DR, Halcomb WW. Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother 1984;25:20-4.
87. Smith MBH, Feldman W. Over-the-counter cold medications. A critical review of clinical trials between 1950 and 1991. JAMA 1993;269: 2258-63.
88. Akerlund A, Klint T, Olen L, Rundcrantz H. Nasal decongestant effect of oxymetazoline in the common cold: a objective dose-response study in 106 patients. J Laryngol Otol 1989; 103:743-6.
89. Doyle WJ, Riker DK, McBride TP, et al. Therapeutic effects of an anticholinergic-sympathomimetic combination in induced rhinovirus colds. Ann Otol Rhinol Laryngol 1993;102: 521-7.
90. Sperber SJ, Sorrentino JV, Riker DK, Hayden FG. Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bull N Y Acad Med 1989;65:145-60.
91. Connell JT, Linzmayer MI. Comparison of nasal airway patency changes after treatment with oxymetazoline and pseudoephedrine. Am J Rhinol 1987;1:87-94.
92. Gaffey MJ, Gwaltney JM, Jr, Dressier WE, et al. Intranasally administered atropine methonitrate treatment of experimental rhinovirus colds. Am Rev Respir Dis 1987;135: 241-4.
93. Gaffey MJ, Hayden FG, Boyd JC, Gwaltney JM, Jr. Ipratropium bromide treatment of experimental rhinovirus secretion. Antimicrob Agents Chemother 1988;32:1644-7.
94. Duckhorn R, Grossrnan J, Posner M, et al. A double-blind, placebo-controlled study of the safety and efficacy of ipratropium bromide nasal spray versus placebo in patients with the common cold. J Allergy Clin Immunol 1992;90:1076-82.
95. Diamond L, Dockhorn RJ, Grossrnan J, et al. A dose-response study of the efficacy and safety of ipratropium bromide nasal spray in the treatment of the common cold. J Allergy Clin Immunol 1995;95:1139-46.
96. Hayden FG, Diamond L, Wood PB, et al. Effectiveness and safety of intranasal ipratropium bromide in common colds: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:89-97.
97. Sakchainanont B, Chantarojanasiri T, Ruangkanchanasetr S, et al. Effectiveness of antihistamines in common cold. J Med Assoc Thai 1990;73: 96-101.
98. Howard JC, Jr, Kantner TR, Lilienfield LS, et al. Effectiveness of antihistamines in the symptomatic management of the common cold. JAMA 1979;242:2414-7.
99. Gaffey MJ, Gwaltney JM, Jr, Sastre A, et al. Intranasally and orally administered antihistamine treatment of experimental rhinovirus colds. Am Rev Respir Dis 1987;136:556-60.
100. Doyle WJ, McBride TP, Skoner DP, et al. A double-blind, placebo-controlled clinical trial of the effect of chlorpheniramine on the response of the nasal airway, middle ear and eustachian tube to provocative rhinovirus challenge. Pediatr Infect Dis J 1988;7:229-38.
101. Gwaltney JM, Jr, Park J, Paul RA, et al. Randomized controlled trial of clemastine fumarate for treatment of experimental rhinovirus colds. Clin Infect Dis 1996;22:656-62.
102. Turner RB, Sperber SJ, Sorrentino JV, et al. Effectiveness of clemastine fumarate for treatment of rhinorrhea and sneezing associated with the common cold. Clin Infect Dis (in press).
103. Gaffey MJ, Kaiser DL, Hayden FG. Ineffectiveness of oral terfenadine in natural colds: evidence against histamine as a mediator of common cold symptoms. Pediatr Infect Dis J 1988; 7:223-8.
104. Berkowitz RB, Tinkelman DG. Evaluation of oral terfenadine for treatment of the common cold. Ann Allergy 1991;67:593-7.
105. Curley FJ, Irwin RS, Pratter MR, et al. Cough and the common cold. Am Rev Respir Dis 1988;138:305-11.
106. Wald ER, Reilly JS, Casselbrant M, et al. Treatment of acute maxillary sinusitis in childhood: a comparative study of amoxicillin and cefaclor. J Pediatr 1984;104:297-302.
107. Korppi M, Laurikainen K, Pietikainen M, Silvasti M. Antitussives in the treatment of acute transient cough in children. Acta Paediatr Scand 1991;80:969-71.
108. Tukiainen H, Karttunen P, Silvasti M, et al. The treatment of acute transient cough: a placebo-controlled comparison of dextromethorphan and dextromethorphan-beta2-sympathomimetic combination. Eur J Respir Dis 1986; 69:95-9.
109. Sperber SJ, Hendley JO, Hayden FG, et al. Effects of naproxen on experimental rhinovirus colds. A randomized, double-blind, controlled trial. Ann Intern Med 1992;117:37-41.
110. Kuhn JJ, Hendley JO, Adams KF, et al. Antitussive effect of guaifenesin in young adults with natural colds. Objective and subjective assessment. Chest 1982;82:713-8.
111. Gwaltney JM, Jr. Combined antiviral and antimediator treatment of rhinovirus colds. J Infect Dis 1992;166: 776-82.
112. Sattar SA, Jacobsen H, Springthorpe VS, et al. Chemical disinfection to interrupt transfer of rhinovirus type 14 from environmental surfaces to hands. Appl Environ Microbiol 1993; 59:1579-85.
113. Hendley JO, Mika LA, Gwaltney JM, Jr. Evaluation of virucidal compounds for inactivation of rhinovirus on hands. Antimicrob Agents Chemother 1978;14:690-4.
114. Hayden GF, DeForest D, Hendley JO, Gwaltney JM, Jr. Inactivation of rhinovirus on human fingers by virucidal activity of glutaric acid. Antimicrob Agents Chemother 1984;26: 928-9.
115. Dick EC, Hossain SU, Mink KA, et al. Interruption of transmission of rhinovirus colds among human volunteers using virucidal paper handkerchiefs. J Infect Dis 1986;153:352-6.
116. Hayden GF, Hendley JO, Gwaltney JM, Jr. The effect of placebo and virucidal paper handkerchiefs on viral contamination of the hand and transmission of experimental rhinoviral infection. J Infect Dis 1985;152: 403-7.
117. Hayden GF, Gwaltney JM, Jr, Thacker DF, Hendley JO. Rhinovirus inactivation by nasal tissues treated with virucide. Antiviral Res 1985;5: 103-9.
118. Hayden FG, Gwaltney JM, Jr, Colonno RJ. Modification of experimental rhinovirus colds by receptor blockade. Antiviral Res 1988;9: 233-47.
119. Barrow GI, Higgins PG, Tyrrell DAJ, Andries K. An appraisal of the efficacy of the antiviral R 61837 in rhinovirus infections in human volunteers. Antiviral Chem Chemother 1990;1:279-83.
120. Hayden FG, Andries K, Janssen PA. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother 1992;36:727-32.
121. Douglas RM, Moore BW, Miles HB, et al. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med 1986;314:65-70.
122. Hayden FG, Gwaltney JM, Jr. Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. J Infect Dis 1983;148:543-50.
123. Hayden FG, Gwaltney JM, Jr. Intranasal interferon-alpha, treatment of experimental rhinovirus colds. J Infect Dis 1984;150:174-80.
124. Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM, Jr. Prevention of natural colds by contact prophylaxis with intranasal alpha2-interferon. N Engl J Med 1986;314:71-5.
125. Higgins PG, Al-Nakib W, Willman J, Tyrrell DA. Interferon-beta ser as prophylaxis against experimental rhinovirus infection in volunteers. J Interferon Res 1986;6:153-9.
126. Monto AS, Shope TC, Schwartz SA, Albrecht JK. Intranasal interferon-α2b for seasonal prophylaxis of respiratory infection. J Infect Dis 1986; 154:128-33.
127. Hayden FG, Mills SE, Johns ME. Human tolerance and histopathologic effects of long-term administration of intranasal interferon-α2. J Infect Dis 1983;148:914-21.
128. Samo TC, Greenberg SB, Couch RB, et al. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers. J Infect Dis 1983;148:535-42.
129. Samo TC, Greenberg SB, Palmer JM, et al. Intranasally applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose. J Infect Dis 1984;150:181-8.
130. Scott GM, Onwubalili JK, Robinson JA, et al. Tolerance of one-month intranasal interferon. J Med Virol 1985; 17:99-106.